A new variant called Cicada is spreading through 25 U.S. states. Most coverage focuses on its mutations, its immune evasion, its symptoms. Almost none asks the question that actually matters: for someone on their third or fourth infection, what does one more turn of the wheel do to a body that never fully recovered from the last?
The answer is in the data. And the data says this: each COVID infection ratchets up your risk of chronic illness, organ damage, and Long COVID. The mechanism is not random chance — it is cumulative biological corrosion. And unlike a coin flip, the ratchet only turns one direction.
The Number
That number comes from the RECOVER-EHR consortium, the largest electronic health record study of Long COVID in the world. It means that among people who've been infected three times — which, six years into the pandemic, is the majority of the population — more than one in three are carrying persistent symptoms. That's not a tail risk. That's a population-level chronic disease burden.
The Paradox at the Center
Here's what makes the reinfection story intellectually complicated — and why most coverage gets it wrong.
In a cohort of 22,496 Quebec healthcare workers (Carazo et al., IJID, 2025), reinfections carried 40% lower per-infection Long COVID risk than first infections. Omicron infections were 34% less risky than ancestral variants. From an individual-infection standpoint, each subsequent exposure looked less dangerous.
This is the finding that gets weaponized. See? It gets milder. Natural immunity works. Move on.
But the same study found that cumulative burden still increased with number of infections. And 79% of all Long COVID cases in their cohort were associated with Omicron — because its massive transmissibility produced far more total infections. A smaller risk multiplied by a larger number of exposures equals a bigger problem.
"Each individual rainstorm may be gentler than the last. The rust still accumulates."
This is the paradox: the per-infection probability of Long COVID may decrease with immune experience, but the biological damage is additive. Each infection doesn't reset the clock. It adds to an already-corroded system. The Quebec data tells both halves of the story — and most people only hear one.
The Evidence Across 2.6 Million Patients
Ten studies, spanning five countries and more than 2.6 million patients, converge on the same conclusion. The numbers vary by cohort, methodology, and variant era — but the direction is unanimous.
The Landmark: Al-Aly et al.
The first and still most cited study came from the U.S. Veterans Affairs database (Al-Aly et al., Nature Medicine, 2022): 443,588 single-infection vs. 40,947 reinfection patients, plus 5.3 million uninfected controls. Reinfection versus no reinfection: death HR 2.17, hospitalization HR 3.32. Every organ system showed elevated postacute risk — pulmonary, cardiovascular, hematological, renal, neurological, GI, musculoskeletal, mental health, endocrine. Risks persisted beyond 6 months. Vaccination status made no difference.
The RECOVER Confirmation
Three years later, the RECOVER consortium validated the same pattern at larger scale. In 424,616 matched pairs across 85 hospitals (medRxiv, Aug 2025), reinfected adults had 35% higher Long COVID incidence than non-reinfected — 12.1% vs. 8.7%. Vaccination post-first-infection partially attenuated the risk (RR 1.19 vs. 1.33-1.45 unvaccinated), but didn't eliminate it.
The Organ Map
The most granular organ-specific data comes from Singapore. Lim et al. (BMC Global Public Health, 2025) tracked 57,222 reinfected individuals against 1.2 million single-infection and 3.4 million uninfected controls. The organ-level hazard ratios tell you exactly where the damage goes:
| Organ System | Hazard Ratio | 95% CI |
|---|---|---|
| Respiratory | 1.63 | 1.44–1.83 |
| Neurological | 1.32 | 1.23–1.42 |
| Renal | 1.28 | 1.12–1.47 |
| GI | 1.26 | 1.16–1.38 |
| Endocrine | 1.26 | 1.18–1.35 |
| Cardiovascular | 1.20 | 1.09–1.32 |
Crucially, these risks did not attenuate over time since infection. And they persisted among the fully vaccinated and boosted. The damage is not transient.
The Children
The most alarming signal in the reinfection literature comes from pediatrics.
The RECOVER-EHR pediatric study (Lancet Infectious Diseases, September 2025) followed 465,717 children and adolescents. The findings:
This pattern held across vaccinated and unvaccinated children, across all severities, all ages, all genders, all races. The accompanying editorial estimated approximately 6 million U.S. children may be affected by post-COVID sequelae — more than the number with asthma.
Children's bodies are not more resilient to cumulative viral injury. They are more exposed to it, because they have decades of reinfections ahead of them.
The COPD Warning
If you want to see where cumulative reinfection damage ends, look at COPD patients. Lee et al. (BMJ Open, February 2026) tracked 313,760 COPD patients in South Korea. The dose-response is stark: one COVID infection raised exacerbation risk (aHR 1.64) and mortality (aHR 2.25). Three or more infections: exacerbation aHR 2.41, mortality aHR 2.93.
This is what the ratchet looks like in a population with existing pulmonary compromise. Each infection doesn't just add risk — it accelerates the progression of the underlying disease. The lung function lost to infection doesn't return. The inflammation adds to inflammation already present. The system degrades.
Why the Ratchet Only Turns One Direction
The population-level data tells you that cumulative damage occurs. The mechanistic research tells you why it can't reverse. Seven biological processes — each documented in separate studies, each covered in previous posts on this blog — explain the irreversibility.
These are not theoretical risks. Each mechanism has been independently documented, each connects to a body of primary research, and each shares a critical property: irreversibility.
Bone marrow stem cells don't un-reprogram themselves (Post #19). NAD+ reserves don't spontaneously refill when CD38 remains elevated (Post #20). Long-lived plasma cells, once established in marrow niches, produce autoantibodies for years to decades (Post #21). Amyloid fibrin microclots don't dissolve on their own (Post #14). Small nerve fibers regenerate at roughly 1 mm/day — if the ongoing mast cell inflammation allows it, which it often doesn't (Post #16). Orexin neurons, once killed, are gone forever (Post #17). And the neurodegeneration pipeline — choroid plexus inflammation, chronic monocyte activation, epigenetic aging — compounds with every systemic inflammatory insult (Post #22).
This is why the Quebec paradox makes biological sense. Each individual infection may trigger less acute immune activation than the first. But the damage it adds is permanent. A corroded pipe doesn't care that this year's acid was diluted.
The Corroborating Evidence
Beyond the studies above, three additional datasets strengthen the pattern:
The INSPIRE registry (Clinical Infectious Diseases, September 2025) followed 886 individuals, of whom 415 were reinfected. Omicron-Omicron reinfections — the most common pattern in 2024-2026 — occurred at shorter intervals and carried increased risk of long-term symptoms. Variant timing matters: the virus isn't becoming uniformly safer with each round.
A Barcelona consortium study of 192,651 residents found Long COVID prevalence 3-10× higher in those with three or more infections versus one. Thrombotic events doubled from 2020-2024 across all groups, and 26% of cases were previously undiagnosed — identified only through active survey.
A Frontiers cohort (March 2026) of 2,792 participants found 6.52% LC prevalence — lower than many prior estimates, suggesting hybrid immunity from repeated exposure may attenuate some risk. This nuances the narrative: not every infection is equally dangerous, and accumulated immune experience does provide partial protection. But partial protection is not immunity, and 6.52% of a repeatedly infected population is still tens of millions of people.
What Slows the Ratchet
Vaccination slows it. In the RECOVER-EHR adult data, vaccination post-first-infection reduced the reinfection-associated LC risk ratio from 1.33-1.45 to 1.19. That's not elimination — it's attenuation. The adolescent vaccine protection data from RECOVER's pediatric observational study shows vaccinated 12-17 year-olds were roughly one-third less likely to develop Long COVID.
But vaccination doesn't stop the ratchet. It slows it. And as we saw in yesterday's JAK inhibitor analysis, even targeted immunomodulation may not undo the epigenetic reprogramming already locked in at the bone marrow level. The treatments currently in trials — baricitinib, abrocitinib, upadacitinib — might suppress the inflammatory output, but they can't un-turn the ratchet's previous clicks.
The only intervention that prevents cumulative damage from the next infection is preventing the next infection.
Year Six
We are in the sixth year of SARS-CoV-2 circulation. Seroprevalence surveys suggest the majority of the global population has been infected at least twice. Many have been infected three or more times. The ratchet has been turning, quietly, for years.
The Cicada variant is now circulating in at least 25 U.S. states, driving 30% of cases in parts of Europe. It may not be more severe than its predecessors — early data suggest it isn't. But severity isn't the point. The point is that each additional wave, each additional infection, each additional turn of the ratchet adds damage that doesn't heal. The question isn't whether Cicada is dangerous. The question is what Cicada does to a body that has already been through three rounds of bone marrow reprogramming, microclot formation, nerve damage, and immune exhaustion.
Six million American children may already carry post-COVID sequelae. Forty-four million adults are estimated to have or have had Long COVID. The per-infection risk is declining. The cumulative burden is growing. Both of those statements are true simultaneously, and understanding why requires holding the paradox without collapsing it.
The ratchet only turns one direction. The only question left is how many more turns we'll accept before we start counting them.
Sources: Al-Aly et al., Nature Medicine 2022 · RECOVER-EHR Adult, medRxiv 2025 · RECOVER-EHR Pediatric, Lancet ID 2025 · Lim et al., BMC GPH 2025 · Carazo et al., IJID 2025 · INSPIRE, CID 2025 · Lee et al., BMJ Open 2026 · Barcelona CST, Vaccines 2025 · Frontiers Cohort 2026 · CIDRAP reinfection reporting